ENVISAGENICS
Envisagenics focus on the discovery of RNA therapeutics. Their mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Their breakthrough technolo... gy, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug targets, and develop RNA therapeutics through partnerships and collaborations with Biopharma. Their in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs. Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory.
ENVISAGENICS
Industry:
Artificial Intelligence Bioinformatics Biotechnology Machine Learning Therapeutics
Founded:
2014-04-22
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.envisagenics.com
Total Employee:
11+
Status:
Active
Contact:
(516)847-5485
Email Addresses:
[email protected]
Total Funding:
27.06 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins
Current Advisors List
Current Employees Featured
Founder
Investors List
National Cancer Institute
National Cancer Institute investment in Grant - Envisagenics
M12 - Microsoft's Venture Fund
M12 - Microsoft's Venture Fund investment in Series A - Envisagenics
New York Ventures
New York Ventures investment in Series A - Envisagenics
Madrona Venture Group
Madrona Venture Group investment in Series A - Envisagenics
Third Kind Venture Capital
Third Kind Venture Capital investment in Series A - Envisagenics
Dynamk Capital
Dynamk Capital investment in Series A - Envisagenics
Red Cell Partners
Red Cell Partners investment in Series A - Envisagenics
National Cancer Institute
National Cancer Institute investment in Grant - Envisagenics
National Institutes of Health
National Institutes of Health investment in Grant - Envisagenics
Madrona Venture Group
Madrona Venture Group investment in Seed Round - Envisagenics
Official Site Inspections
http://www.envisagenics.com
- Host name: 172.67.195.95
- IP address: 172.67.195.95
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago